Background {#Sec1}
==========

Peripheral arterial disease (PAD), especially atherosclerotic obliterans, is usually characterized by chronic inflammatory disease \[[@CR1]\]. The inflammatory reaction, which is affected by local inflammation due to leukocytes, monocytes and macrophages, leads to endothelial dysfunction \[[@CR2]\]. Although platelets have been shown to contribute to the development of atherosclerotic disease \[[@CR3]\], the potential role of coagulation proteins remains to be proven. However, several experimental studies have shown a significant association between hypercoagulability and the development of atherosclerosis \[[@CR4]\].

A number of measures are used to evaluate coagulability, including the prothrombin time, the international normalized ratio (PT-INR), and the activated partial thromboplastin time (APTT). Even though these tests might evaluate the bleeding tendency, they do not properly reflect the actual hypercoagulable status in vivo \[[@CR5]\]. Furthermore, several enzymatic factors in the plasma components and blood cells have shown to affect hypercoagulability, which are not taken into account in the PT-INR and APTT tests \[[@CR6]\].

Dielectric blood coagulometry (DBCM), is a recently developed method of evaluating coagulability \[[@CR7], [@CR8]\]. DBCM calculates the temporal changes in whole blood dielectric permittivity, and evaluates the coagulable status. Hasegawa et al. \[[@CR9]\] reported the application of DBCM in the evaluation of hypercoagulability in patients with several risk factors for atherosclerosis; however, no studies have used DBCM to investigate coagulability in PAD patients.

In the present study, we conducted the DBCM test for the patients with PAD. Furthermore, we investigated the relationships between the DBCM results and various parameters.

Methods {#Sec2}
=======

Patient selection {#Sec3}
-----------------

Between September 2014 and June 2015, 49 patients with PAD due to atherosclerosis who were treated at the outpatient clinic of Tokyo Medical and Dental University Hospital were recruited for the present study. All of the patients provided their written informed consent, then we enrolled. This study was approved by the ethics committee of Tokyo Medical and Dental University (No. 701).

PAD was diagnosed based on the presence of \>50% vessel stenosis due to lesions in the lower limbs. We mainly assessed the vessel stenosis by computed tomography angiography. In the cases with contraindication of using contrast media, such as chronic kidney disease and allergy, we evaluated the stenosis using magnetic resonance angiography and/or duplex ultrasound sonography. In this study, PAD of all patients was due to the atherosclerosis. Furthermore, in the present study, we included patients who previously underwent revascularization procedures to treat PAD lesions. We excluded the patients who had a history of recent malignant disease, systemic inflammatory disease, treatment with anticoagulants, or abnormal bleeding.

We retrospectively obtained the patients' demographics, medications, and medical histories using a dedicated database. The patients' medical records were reviewed as described below. Hypertension was defined as a systolic blood pressure of \>130 mmHg, a diastolic blood pressure of \>80 mmHg, or a history of treatment for hypertension. Dyslipidemia was defined as a serum low-density lipoprotein cholesterol level of \>140 mg/dl, a high-density lipoprotein cholesterol level of \<40 mg/dl, a triglyceride level of \>150 mg/dl, or a history of treatment for dyslipidemia. Coronary arterial disease (CAD) was defined as the presence of angina pectoris, myocardial infarction or both, as documented on coronary angiography or based on a history of having undergone any coronary artery revascularization procedures. Cerebrovascular disease (CVD) was defined as a history of stroke, transient ischemic attacks, carotid artery revascularization, or cerebral hemorrhage. Chronic kidney disease (CKD) was defined as an estimated glomerular filtration rate of \<60 ml/min/1.73 m^2^, which was calculated by the serum creatinine level, age, and gender. Diabetes mellitus (DM) was defined as a fasting blood glucose level of \>126 mg/dl, a hemoglobin A1c level of \>6.5%, or the use of antidiabetes medication. The severity of PAD was assessed by the measurement of the ankle brachial pressure index (ABI), which was calculated as the ankle systolic blood pressure divided by the brachial systolic blood pressure using a VasoGuard P84™ system (SciMed Ltd., Bristol, UK). Furthermore, the clinical severity of PAD was assessed by the Rutherford classification \[[@CR10]\].

The measurement of the collected blood samples {#Sec4}
----------------------------------------------

After the patients had fasted for at least 12 h, we collected blood samples by venipuncture. The samples were kept in tubes containing 3.13% sodium citrate. Complete blood cell counts, biochemistry examinations, and coagulation tests were conducted via standard laboratory methods in our hospital. The blood samples that were used for DBCM were kept at room temperature and were examined at 3--5 h after collection.

Dielectric blood coagulometry {#Sec5}
-----------------------------

We performed DBCM using a prototype dielectric coagulometer (Sony Corp., Tokyo, Japan) in accordance with the methods of previous studies \[[@CR7], [@CR8], [@CR11]\]. In summary, we kept the blood samples at 37 °C, and DBCM was completed at 60 min after recalcification. The measurement frequency at which DBCM measured the dielectric permittivity was ranged from 100 Hz to 10 MHz, the sampling intervals were 1 min. DBCM was performed using a 180-μl citrated whole blood sample, and blood coagulability was assessed by recalcification using 15 μl of 308 mM CaCl~2~. A typical DBCM result is shown in a 3D plot of permittivity against the time and frequency in Fig. [1a](#Fig1){ref-type="fig"}. Hayashi et al. \[[@CR8]\] reported that the time of dielectric coagulation obtained from the time-dependent permittivity has been well correlated with the coagulation time which was evaluated by the rheologic measurement. Then, coagulability was evaluated as the normalized permittivity according to the time series and frequency. Hayashi et al. \[[@CR7]\] reported that the monitoring of the dielectric response at 1 MHz made it possible to obtain the clotting time, while Hasegawa et al. \[[@CR9]\] evaluated the temporal change in the dielectric permittivity at 10 MHz, and showed a significant correlation with a hypercoagulable status. We therefore measured the change of permittivity at both 1 and 10 MHz, and evaluated the coagulability. DBCM showed a gradual increase in dielectric permittivity, which indicated the temporal acceleration of the coagulation. We therefore defined "T~max~," which represents the time from recalcification to maximum normalized permittivity, as a parameter of coagulability (Fig. [1b](#Fig1){ref-type="fig"}). The repuroducibility of this DBCM test has been already evaluated by previous study \[[@CR9]\].Fig. 1Temporal changes in the dielectric permittivity. **a** The normalized permittivity after recalcification is plotted according to the time and frequency. **b** A normalized permittivityat 1 MHz or 10 MHz is plotted, and calculates Tmax. *Tmax*, the time from recalcification to maximum normalized permittivity

Statistical analysis {#Sec6}
--------------------

The continuous variables are expressed as the median and interquartile range (IQR), and the categorical variables are expressed as the frequency and percentage. Statistical significance was assessed using the Mann-Whitney *U* test for comparisons between two groups. Correlation was assessed using Spearman's rank correlation coefficient, which reflects the degree of correlation between variables. *P* values \<0.05 were considered to indicate statistical significance. The statistical analyses were performed using the Stat View software program (version 5, Abacus Concept Inc., Berkley, CA, USA).

Results {#Sec7}
=======

Patient demographics {#Sec8}
--------------------

We evaluated 49 (41 males and 8 females) PAD patients in the present study. The median age was 70 years (IQR, 63--77), and the median body mass index was 22.7 kg/m^2^ (IQR, 20.8--25.1). The documented comorbidities included smoking history (85.7%), hypertension (65.3%), dyslipidemia (51.0%), CKD (22.4%), CVD (18.4%), and CAD (10.2%). All patients with DM (44.9%) were diagnosed due to the medication of antidiabetes. The patient's medications included Ca-blockers, *n* = 24 (49.0%); β-blockers, *n* = 6 (12.2%); angiotensin converting enzyme inhibitors, *n* = 2 (4.1%); angiotensin II receptor blockers, *n* = 20 (40.8%); statins, *n* = 22 (44.9%); and antiplatelet drugs, *n* = 44 (89.8%). None of the patients took anticoagulant drugs. By the Rutherford classification, 21 patients were classified as category 1, 14 patients as category 2, 8 patients as category 3, and 6 patients were divided in category 4.

Comparisons according to the patient demographics {#Sec9}
-------------------------------------------------

We performed DBCM and calculated the T~max~ at 1 MHz and 10 MHz. The median T~max~ values at 1 MHz and 10 MHz were 1320 s (IQR, 1140--1620 s) and 1560 s (IQR, 1380--1920 s), respectively. We assessed the DBCM tests according to the patients' comorbidities and demographics (Table [1](#Tab1){ref-type="table"}). The patients with DM showed significantly shorter T~max~ values than those without DM (*P* = 0.010 at 1 MHz, and *P* = 0.011 at 10 MHz, respectively). Interestingly, the T~max~ values of the patients who were receiving antiplatelet therapy did not differ to a statistically significant extent from those of the patients who did not receive antiplatelet therapy.Table 1Patient demographics and comparisons1 MHz, Tmax10 MHz, TmaxVariablesNumberMedian*P*-valueMedian*P*-valueGender (Male: Female)41: 81320: 12600.5691620: 15000.705Smoking history (+: -)42: 71320: 13200.8411560: 18000.852Hypertension (+: -)32: 171290: 14400.3381500: 17400.152Dyslipidemia (+: -)25: 241260: 14400.1731500: 16500.652Coronary artery disease (+: -)5: 441320: 13200.9871740: 15600.741Cerebrovascular disease (+: -)9: 401200: 14100.14731500: 16500.224Chronic kidney disease (+: -)11: 381080: 13800.1671260: 17100.052Diabetes mellitus (+: -)22: 271170: 15000.0101470: 18000.011Ca-blocker (+: -)24: 251320: 13200.7111500: 16800.331β-blocker (+: -)6: 431500: 13200.4921680: 15600.783ACE-I (+: -)2: 471440: 13200.6671620: 15600.859ARB (+: -)20: 291290: 13200.7141500: 16800.154Statin (+: -)22: 271260: 14400.4871620: 15600.840Antiplatelet (+: -)44: 51350: 13200.6201560: 16200.408*IQR* interquartile range; *ACE-I* angiotensin converting enzyme -- inhibitor; *ARB* angiotensin II receptor blocker

The correlations between T~max~ and the other parameters {#Sec10}
--------------------------------------------------------

The correlations between T~max~ and each of the parameters are shown in Table [2](#Tab2){ref-type="table"}. With the exception of the APTT (ρ = 0.286, *P* = 0.048 at 1 MHz, and ρ = 0.301, *P* = 0.037 at 10 MHz, respectively), none of the factors was significantly correlated with the T~max~ value.Table 2Correlations with several parameters1 MHz, Tmax10 MHz, TmaxVariablesMedian, \[IQR\]ρ, *P*-valueρ, *P*-valueAge (years)70, \[63-77\]−0.219, 0.129−0.219, 0.130BMI (kg/m^2^)22.7, \[20.8-25.1\]0.080, 0.5770.035, 0.807ABI0.95, \[0.78-1.07\]0.019, 0.8950.036, 0.803White blood cell (/μl)6400, \[5100-7600\]−0.184, 0.202−0.162, 0.262Hemoglobin (g/dl)13.9, \[12.9-15.1\]0.203, 0.1590.255, 0.078Platelet (×10^4^/μl)22.7, \[20.2-26.9\]−0.126, 0.382−0.060, 0.678PT-INR0.98, \[0.94-1.01\]0.223, 0.1220.125, 0.385APTT (sec)28.9, \[27.5-31.6\]0.286, 0.0480.301, 0.037Fibrinogen (mg/dl)302, \[269-339\]−0.207, 0.151−0.058, 0.688Albumin (g/dl))4.1, \[3.8-4.4\]0.213, 0.1890.212, 0.192Creatinine (mg/dl)0.89, \[0.75-1.0\]−0.104, 0.472−0.107, 0.457Total cholesterol (mg/dl)185, \[166.3-207.8\]−0.057, 0.6970.048, 0.741Triglycerides (mg/dl)118, \[80.5-165\]0.061, 0.6810.100, 0.500LDL (mg/dl)106, \[94.5-121.8\]0.195, 0.2240.182, 0.256*BMI* body mass index; *ABI* ankle brachial pressure index; *APTT* activated partial thromboplastin time; *LDL* low-density lipoprotein; *IQR* interquartile range; *PT-INR* Prothrombin time -- International normalized ratio

Discussion {#Sec11}
==========

A comprehensive test that can evaluate the coagulable status is essential for the effective control of coagulability. DBCM might meet these necessities by measuring the changes in the permittivity \[[@CR7]\]. In the present study, we evaluated the changes in permittivity at 1 MHz and 10 MHz. The dielectric permittivity of blood mainly changes at frequencies that range from hundreds of kilohertz to 10 MHz. The change occurs due to the accumulation of charge at the interface between the cytoplasm and the erythrocyte membrane \[[@CR12]\]. Hayashi et al. \[[@CR11]\] reported that the temporal changes in permittivity at 1 MHz reflected the clotting time. On the other hand, Hasegawa et al. \[[@CR9]\] reported that DBCM represented a gradual increase in the dielectric permittivity from 2.5--16 MHz, and they focused on the temporal change in the dielectric permittivity at 10 MHz. Thus, both 1 and 10 MHz might be reasonable frequencies for evaluating coagulability based on the temporal changes in the permittivity. Moreover, Hayashi et al. \[[@CR7]\] reported that the T~max~ parameter, which was referred to as "T~i(DS)~" in their report, was useful for evaluating the coagulability. In our study, we evaluated the temporal changes in permittivity at frequency of 1 and 10 MHz, and calculated the 'T~max~' value. We showed the significant correlation with the T~max~ and APTT, which represented the coagulable status, and DBCM might indicate the coagulability.

Our study showed a statistically significant correlation between the T~max~ and APTT values. Shortened APTTs are generally considered to be laboratory artifacts that arise from problematic venipuncture. However, there is increasing evidence to support that shortened APTT values may in some cases reflect a hypercoagulable state, which is potentially associated with an increased risk of thromboembolism \[[@CR13], [@CR14]\]. Tripodi et al. \[[@CR15]\] reported that hypercoagulability, as detected by a shortened APTT value, was significantly associated with the occurrence of venous thromboembolism (VTE). In line with these reports, Hayashi et al. \[[@CR8]\] found that DBCM allows quantitative monitoring of blood coagulability and that it is promising technique for the evaluation of VTE. Even though this mechanism has been uncertain, Hasegawa et al. \[[@CR9]\] reported that the APTT was positively correlated with the end of acceleration time, which is almost the same as the T~max~. The APTT might reflect the intrinsic pathways of coagulation cascade \[[@CR16]\]. Therefore, the T~max~ might also be affected by the intrinsic pathways, and potentially be used to assess the coagulable status as same as the APTT.

Patients with DM showed significantly shorter T~max~ values at 1 and 10 MHz than those without DM in the present study. This is because hyperglycemia contributes to the hyperfibrinogemia and activates the coagulative cascade, leading to an increase in thrombin formation and in the levels of fibrinogen degradation products \[[@CR17]\]. However, the exact mechanisms of the development of the hypercoagulable state in diabetic patients is likely to multifactorial and is not yet completely understood. Lippi et al. \[[@CR18]\] reported that the APTT values were significantly shortened in DM patients. Similarly, Zhao et al. \[[@CR19]\] found that the DM patients showed statistically shortened APTT values in comparison to patients without DM. Similarly, we revealed that DM patients showed significantly shortened APTT values (median, 28.5 s) in comparison to patients without DM (29.4 s) (*P* \< 0.001). Thus, the present study shows that the T~max~ values yielded by DBCM are significantly correlated with both the coagulable state (as reflected by the APTT) and a hyperglycemic status, which leads to hypercoagulability.

There were no significant differences in the T~max~ values of patients who were treated with/without antiplatelet drugs. The same result was shown in a previous report \[[@CR9]\]. In addition to DBCM, several modalities, including thromboelastrography and rotational thromboelastometry, can be used to assess whole blood coagulability. These modalities can be used to evaluate the effects of antiplatelet treatment \[[@CR20]\]. Even though we theoretically evaluated the effects of antiplatelet drugs, which led to an increased T~max~ value, we did not observe any differences. This might be due to the small sample size, which was one of the limitations associated with the present study. Both the APTT value and the presence of DM might have affected the association between the T~max~ and the use of antiplatelet drugs. Although the platelet counts of diabetic patients are normal, multiple studies have shown evidence of enhanced activation or increased platelet activity in DM patients \[[@CR21]\]. Our study included 15 patients who received sarpogrelate hydrochloride as antiplatelet therapy. The drug, which is a selective 5-hydroxytryptaminen 2A receptor antagonist that is used in the treatment of diabetic patients with PAD, suppresses platelet aggregation \[[@CR22]\]. It was very interesting that antiplatelet drugs, including aspirin, clopidogrel, and cilostazol did not significantly affect the patients' T~max~ values, but that patients who were treated with sarpogrelate hydrochloride showed increased T~max~ values at 1 and 10 MHz in comparison to patients who did not receive the drug (1 MHz: median T~max~, 1500 vs. 1260, *P* = 0.044; 10 MHz: 1860 vs. 1500, *P* = 0.027). These discrepancies might be due to the small number of subjects and/or a bias associated with the inclusion criteria. Future studies in a larger population might reveal the effects of antiplatelet drug by DBCM.

Conclusions {#Sec12}
===========

We herein demonstrated that the measurement of the T~max~ value by DBCM detected a change in the coagulable status according to the APTT value and the presence of DM. Even though the use of DBCM did not reveal the exact effects of antiplatelet drugs in the present study, the T~max~ values of patients who received sarpogrelate hydrochloride, an antiplatelet drug, were increased in comparison to those of patients who did not receive the drug. A more sensitive measurement with DBCM might therefore be successful in elucidating the effects of antiplatelet drugs.
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